I-MAB (IMAB) files 6-K with updated Phase I givastomig poster

Rhea-AI Filing Summary

I-MAB filed a Form 6-K as a foreign private issuer to furnish new clinical information to the market. The filing mainly serves to make Exhibit 99.1 part of several existing Form F-3 and Form S-8 registration statements. Exhibit 99.1 is a scientific poster describing updated safety, efficacy and biomarker analysis from a Phase I monotherapy study of givastomig, described as a novel Claudin 18.2/4-1BB bispecific antibody, in Claudin 18.2 positive advanced gastroesophageal carcinoma. By incorporating this poster into its registration statements, the company is formally linking these early-stage clinical data to its U.S. securities offering documents.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39173

I-MAB

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

DOCUMENTS INCORPORATED BY REFERENCE

Exhibit 99.1 set forth in this Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842 and File No. 333-290195) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Poster - Updated Safety, Efficacy and Biomarker Analysis from the Phase I Monotherapy Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	I-MAB
	By	:	/s/ Xi-Yong Fu
	Name	:	Xi-Yong (Sean) Fu
	Title	:	Chief Executive Officer

Date: October 24, 2025

FAQ

What did I-MAB (IMAB) disclose in this Form 6-K filing?

I-MAB furnished a Form 6-K to submit a poster as Exhibit 99.1. The poster presents updated safety, efficacy and biomarker analysis from a Phase I monotherapy study of givastomig in advanced gastroesophageal carcinoma.

What is the Exhibit 99.1 poster about in I-MABs Form 6-K?

Exhibit 99.1 is a poster detailing updated safety, efficacy and biomarker findings. It comes from a Phase I monotherapy study of givastomig, a Claudin 18.2/4-1BB bispecific antibody, in Claudin 18.2 positive advanced gastroesophageal carcinoma.

How is the Form 6-K content used in I-MAB (IMAB) registration statements?

The Form 6-K states that Exhibit 99.1 is incorporated by reference into I-MABs Form F-3 and multiple Form S-8 registration statements, making the poster part of those offering documents from the furnishing date.

What type of drug is givastomig in I-MABs Phase I study?

Givastomig is described as a novel Claudin 18.2/4-1BB bispecific antibody. The poster examines its safety, efficacy and biomarker profile when used as a monotherapy in Claudin 18.2 positive advanced gastroesophageal carcinoma patients.

What stage of clinical development is givastomig in according to the filing?

The filing references a Phase I monotherapy study of givastomig. The Exhibit 99.1 poster provides updated analysis from this early-stage trial in Claudin 18.2 positive advanced gastroesophageal carcinoma.

Who signed I-MABs October 2025 Form 6-K report?

The Form 6-K was signed on behalf of I-MAB by Xi-Yong (Sean) Fu. He is identified in the document as the companys Chief Executive Officer as of the October 24, 2025 date.